Hippo Signaling Pathway in Parkinson's Disease

Hippo Signaling Pathway in Parkinson's Disease

Overview

The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, apoptosis, and tissue homeostasis. Originally discovered in Drosophila melanogaster as a regulator of tissue growth, this pathway has emerged as a critical player in neurodegenerative diseases, particularly Parkinson's Disease (PD). The pathway controls neuronal survival through a kinase cascade involving MST1/2, LATS1/2, and the downstream effectors YAP (Yes-Associated Protein 1) and TAZ (WWTR1).

In the context of Parkinson's Disease, the Hippo pathway has garnered significant attention due to its role in regulating dopaminergic neuron survival, its interaction with alpha-synuclein aggregation, and its cross-talk with mitochondrial quality control mechanisms. This page provides a comprehensive mechanism model linking Hippo pathway dysregulation to PD pathophysiology.

Canonical Hippo Pathway Architecture

Core Kinase Cascade

The Hippo pathway consists of a serial kinase cascade that ultimately controls the subcellular localization and activity of YAP and TAZ:

```mermaid
flowchart TD
A["Cellular Stress<br/>DNA damage, Oxidative stress"] --> B["MST1/2 Activation"]
B --> C["SAV1 Recruitment"]
C --> D["LATS1/2 Phosphorylation"]
D --> E["MOB1A/B Binding"]
E --> F["YAP/TAZ Phosphorylation"]
F --> G["14-3-3 Binding"]
G --> H["Cytoplasmic Retention"]
H --> I["Proteasomal Degradation"]

Hippo Signaling Pathway in Parkinson's Disease

Overview

The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, apoptosis, and tissue homeostasis. Originally discovered in Drosophila melanogaster as a regulator of tissue growth, this pathway has emerged as a critical player in neurodegenerative diseases, particularly Parkinson's Disease (PD). The pathway controls neuronal survival through a kinase cascade involving MST1/2, LATS1/2, and the downstream effectors YAP (Yes-Associated Protein 1) and TAZ (WWTR1).

In the context of Parkinson's Disease, the Hippo pathway has garnered significant attention due to its role in regulating dopaminergic neuron survival, its interaction with alpha-synuclein aggregation, and its cross-talk with mitochondrial quality control mechanisms. This page provides a comprehensive mechanism model linking Hippo pathway dysregulation to PD pathophysiology.

Canonical Hippo Pathway Architecture

Core Kinase Cascade

The Hippo pathway consists of a serial kinase cascade that ultimately controls the subcellular localization and activity of YAP and TAZ:

Key Pathway Components

| Component | Gene | Cellular Function | PD Relevance |
|-----------|------|-------------------|---------------|
| MST1 | [MST1 Gene](/genes/mst1) | Core kinase, stress sensor | Hyperactivated in PD, pro-apoptotic |
| MST2 | [MST2 Gene](/genes/mst2) | Redundant kinase function | Compensatory role in neuron survival |
| SAV1 | SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1 | [LATS1 — Large Tumor Suppressor Kinase 1](/genes/lats1) | Kinase, phosphorylates YAP/TAZ | Tumor suppressor function |
| LATS2 | [LATS2](/genes/lats2) | Redundant kinase | Ubiquitin-mediated degradation |
| MOB1A/B | [MOB1A Gene](/genes/mob1a) | Scaffold for LATS activation | Essential for kinase cascade |
| YAP1 | [YAP1 — Yes-Associated Protein 1](/proteins/yap1-protein) | Transcriptional co-activator | Pro-survival when nuclear |
| TAZ | [WWTR1 (TAZ) — WW Domain Containing Transcription Regulator 1](/proteins/wwtr1-taz-protein) | Transcriptional co-activator | Reduced in PD brains |
| TEAD1-4 | [TEAD1 — TEA Domain Transcription Factor 1](/genes/tead1) | Partner transcription factors | YAP/TAZ nuclear partners |

Pathway Regulation Mechanisms

Canonical (Hippo ON): Under homeostatic conditions, cellular stress activates MST1/2 kinases, which phosphorylate and activate LATS1/2 with SAV1 and MOB1A/B scaffolds. Activated LATS1/2 then phosphorylate YAP/TAZ at Ser127 (YAP) and Ser89 (TAZ). Phosphorylated YAP/TAZ bind 14-3-3 proteins and are retained in the cytoplasm, leading to proteasomal degradation. This prevents pro-survival gene transcription and maintains tissue homeostasis.

Non-canonical regulation: YAP/TAZ can be activated independently of the Hippo kinase cascade through:

• Mechanical force (cell stretching, substrate rigidity)
• G-protein coupled receptor signaling
• Wnt pathway cross-talk
• Oxidative stress response

Evidence of Hippo Pathway Dysregulation in Parkinson's Disease

Findings in Patient Tissue

Multiple studies have documented Hippo pathway dysregulation in PD patient brains:

Evidence from PD Models

Toxin-based models:

• 6-OHDA (6-hydroxydopamine) treatment of dopaminergic cells activates MST1 and promotes YAP phosphorylation and degradation
• MPTP/MPP+ model shows similar MST1 activation pattern
• Rotenone treatment induces YAP cytoplasmic retention

• LRRK2 G2019S mutation (most common genetic cause of PD) is associated with altered LATS1/2 phosphorylation status
• PINK1 deficiency leads to dysregulated MST1 signaling and impaired mitophagy[@pink2022]
• Alpha-synuclein (SNCA) overexpression affects Hippo pathway gene expression

Molecular Mechanisms

YAP/TAZ Interaction with Alpha-Synuclein Aggregation

Direct Protein Interactions

Alpha-synuclein ([SNCA — Alpha-Synuclein](/proteins/alpha-synuclein)) directly interacts with Hippo pathway components through multiple mechanisms:

Indirect Effects on Hippo Signaling

Through mitochondrial dysfunction:

• Alpha-synuclein aggregates impair mitochondrial complex I function
• Reduced ATP leads to AMPK activation, which can inhibit mTOR and affect Hippo signaling
• Mitochondrial ROS activates MST1 kinase

• Alpha-synuclein aggregation impairs autophagy machinery
• Impaired autophagy affects YAP/TAZ turnover
• Autophagy regulates MST1 degradation

Cross-Talk with Other PD-Relevant Pathways

Mitochondrial Quality Control

The Hippo pathway intersects extensively with mitochondrial quality control mechanisms central to PD:

Oxidative Stress Response

MST1 functions as an oxidative stress sensor:

Neuroinflammation

Hippo pathway regulates microglial function and neuroinflammation:

mTOR Pathway Interaction

Therapeutic Implications

Current Drug Targets

| Target | Approach | Development Status | Examples |
|--------|----------|-------------------|----------|
| MST1/2 | Inhibitors | Preclinical | Verteporfin, Darapimod |
| YAP/TAZ | Activators | Preclinical | MST1 inhibitors to prevent degradation |
| TEAD | Agonists | Early research | Peptide agonists |
| LATS1/2 | Activators | Early research | Upstream kinase activators |

Experimental Therapeutics

Gene Therapy Approaches

• Viral vector delivery of YAP1 or WWTR1 (TAZ) to restore pro-survival signaling
• CRISPR-based activation of endogenous YAP/TAZ expression
• siRNA targeting MST1 to reduce pro-apoptotic signaling

Clinical Trials and Research

Currently, no clinical trials specifically target Hippo pathway in PD. However, several clinical trials for related compounds may have implications:

• ClinicalTrials.gov identifiers for mTOR inhibitors (NCT05064133, NCT04269629)
• Ongoing studies of autophagy modulators in PD

Conclusion and Future Directions

The Hippo signaling pathway represents a critical nexus linking multiple pathological mechanisms in Parkinson's Disease. From alpha-synuclein aggregation to mitochondrial dysfunction, Hippo pathway dysregulation contributes to dopaminergic neuron vulnerability through reduced YAP/TAZ pro-survival signaling and enhanced MST1-mediated apoptosis.

Key research directions include:

See Also

• [MST1 Gene](/genes/mst1)
• [MST2 Gene](/genes/mst2)
• [LATS1 — Large Tumor Suppressor Kinase 1](/genes/lats1)
• [LATS2](/genes/lats2)
• [MOB1A Gene](/genes/mob1a)
• [YAP1 — Yes-Associated Protein 1](/proteins/yap1-protein)
• [WWTR1 (TAZ) — WW Domain Containing Transcription Regulator 1](/proteins/wwtr1-taz-protein)
• [TEAD1 — TEA Domain Transcription Factor 1](/genes/tead1)
• [SNCA — Alpha-Synuclein](/proteins/alpha-synuclein)
• [PINK1 (PTEN-Induced Kinase 1](/genes/pink1)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Pages

• [Hippo Pathway in Neurodegeneration](/mechanisms/hippo-pathway-neurodegeneration)
• [YAP/TAZ Signaling in Neurodegeneration](/diseases/neurodegeneration)
• [Alpha](/mechanisms/dopaminergic-neuron-vulnerability)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [LRRK2 in Parkinson's Disease](/genes/park2)
• [PINK1](/genes/pink1)
• [Parkin](/entities/parkin-protein)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Hippo Signaling Pathway in Parkinson's Disease discovered through SciDEX knowledge graph analysis: